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Abstract
Background: Lung cancer is the leading cause of cancer death worldwide and characterized by a poor prognosis.
It has a major impact on the psychological wellbeing of patients and their partners. Recently, it has been shown
that Mindfulness-Based Stress Reduction (MBSR) is effective in reducing anxiety and depressive symptoms in cancer
patients. The generalization of these results is limited since most participants were female patients with breast cancer.
Moreover, only one study examined the effectiveness of MBSR in partners of cancer patients. Therefore, in the present
trial we study the effectiveness of MBSR versus treatment as usual (TAU) in patients with lung cancer and their partners.
Methods/Design: A parallel group, randomized controlled trial is conducted to compare MBSR with TAU. Lung cancer
patients who have received or are still under treatment, and their partners are recruited. Assessments will take place at
baseline, post intervention and at three-month follow-up. The primary outcome is psychological distress (i.e. anxiety and
depressive symptoms). Secondary outcomes are quality of life (only for patients), caregiver appraisal (only for partners),
relationship quality and spirituality. In addition, cost-effectiveness ratio (only in patients) and several process variables are
assessed.
Discussion: This trial will provide information about the clinical and cost-effectiveness of MBSR compared to TAU in
patients with lung cancer and their partners.
Trial registration: ClinicalTrials.gov NCT01494883.
Keywords: Mindfulness-based stress reduction, Lung cancer patients, Partners, Psychological distress, Randomized
controlled trial
Background
With an estimated 1.4 million deaths per year, lung cancer
is the leading cause of death by cancer worldwide. Even
with the best available treatment, five-year survival is
merely 16% and about 60 to 70% of patients die within the
first year after diagnosis [1]. This poor prognosis is often
caused by a late diagnosis as the presentation usually
occurs when the lung cancer is advanced. Patients may de-
velop burdensome symptoms like pain, dyspnoea, fatigue
and cough and they may undergo radical treatment,
including surgery, chemo- and radiotherapy. Not surpris-
ingly, lung cancer has a major impact on the psychological
wellbeing of patients and their family. Akechi and col-
leagues [2] showed that 19% of patients with advanced
lung cancer meets the criteria of psychiatric disorders, es-
pecially depressive and adjustment disorders. Of patients
who had been successfully treated for lung cancer 15%
met the criteria for a minor or major depressive disorder
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[3]. The prevalence rate of depressive and anxiety symp-
toms among lung cancer patients ranges from 20 to 47%
[4-7]. Compared to patients with other cancer diagnoses,
lung cancer patients report the highest rates of distress
(43 to 58%) [8,9] resulting in a lower quality of life [10].
Family, friends and especially partners of patients with
lung cancer also have to deal with its psychological im-
pact [11-14]. Partners not only provide emotional and
practical support, they also have to cope with their own
concerns, including the uncertainty regarding the course
of the illness and the fear of losing their partner [15].
More than 50% of partners of lung cancer patients report
negative emotional effects of caregiving [16]. Around 40%
of partners of patients with advanced lung cancer report
high levels of distress [17]. The relationship between
patient and partner can also be affected by the cancer. It
has been shown that some partners report a lower quality
of their relationship after the diagnosis of lung cancer [18].
Though numerous studies examined the psychological
distress of lung cancer patients and their partners [2-22],
not much research is done on how to alleviate distress
in these groups [23]. In addition, the available studies on
managing the psychosocial care needs of cancer patients
and their families have focused on care at the very end
of life (e.g. [24-26]). Recently, studies have demonstrated
that palliative care initiated early in treatment improves
the quality of life and depressive symptoms of lung
cancer patients [10,27]. This stresses the importance of
integrating psychosocial care for lung cancer patients and
their partners early in the treatment, rather than instigat-
ing it once life-prolonging therapies fail.
In the past ten years MBSR has become a promising
psychosocial intervention for cancer patients. Mindful-
ness is defined as intentionally paying attention to
moment-by-moment experiences in a non-judgmental
way [28]. MBSR is an 8-week group-based training con-
sisting of meditation practices, such as the bodyscan,
gentle yoga, sitting and walking meditation. By repeatedly
bringing attention back to the current experience, partici-
pants gradually learn to disengage from dysfunctional
thoughts and directly experience the emotions and bodily
sensations of the present moment. MBSR aims to provide
participants with the ability to step back from ruminating
about the past or worrying about the future and simply
allow experiences to unfold [28,29]. A recent meta-
analysis [30] of 13 nonrandomized studies and 9 random-
ized controlled trials (RCT) concluded there is positive
evidence for the use of mindfulness-based interventions
in reducing psychological distress in cancer patients.
Among the RCT’s, a reduction in symptom severity was
found for both anxiety and depression corresponding
to moderate pooled controlled effect sizes (Hedges’s
g = 0.37 and Hedges’s g = 0.44, respectively) [30]. Though
mindfulness-based interventions seem to be effective, the
authors note that across studies the majority of participants
were women (85%) and diagnosed with breast cancer
(77%). Compared to breast cancer patients, patients with
lung cancer are more often male, older and have a poorer
prognosis. Furthermore, of these 22 studies only one study
included the partners of the patients showing that partners
also benefit from the MBSR training [31]. This is quite sur-
prising since partners of cancer patients also report high
levels of distress [32].
Aims
The aim of the Mindfulness for Lung Oncology Nijmegen
(MILON) study is to examine the effectiveness of MBSR
compared to TAU in reducing psychological distress
in patients with lung cancer and their partners. We
hypothesize that patients in the MBSR group will report
a lower level of psychological distress (i.e. anxiety and de-
pressive symptoms), higher levels of quality of life, quality
of relationship and spirituality than those in the TAU
group. Medical and societal costs will be lower in the
MBSR versus TAU group. We expect partners in the
MBSR group to report a lower level of psychological dis-
tress and higher levels of caregiver appraisal, relationship
quality and spirituality than their counterparts in the
TAU group. With regard to the working mechanisms
of the MBSR programme, we will examine changes in
mindfulness skills, self-compassion, rumination, intrusion,
avoidance and adherence to MBSR.
Methods/Design
Study design
The design of the ‘MILON’ study is a parallel group
randomized controlled trial with an embedded process
study. Participants are randomized between MBSR and
TAU. The study protocol has been approved by our ethical
review board (CMO Arnhem-Nijmegen) and registered
under number 2011–519.
Participants and procedure
Patients and partners are recruited at the outpatient clinic
of the Department of Pulmonary Diseases, Radboud
University Nijmegen Medical Centre (RUNMC) by a
nurse practitioner and the attending physician. Patients
and partners are invited to participate together but both
are welcome to participate on their own if they do not
have a partner or their partner is not willing to participate.
Patients and/or partners who are interested are provided
with an information leaflet. If they are willing to partici-
pate, they are invited for a research interview, in which in-
and exclusion criteria are assessed and informed consent
is taken.
At other participating hospitals (Department of Pulmonary
Diseases, Canisius-Wilhelmina Hospital, Nijmegen; Depart-
ment of PulmonaryMedicine, Rijnstate, Arnhem; Department
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of Oncology, Elkerliek Hospital, Helmond; Department of
Pulmonary Medicine, Jeroen Bosch Hospital; Department
of Pulmonary Diseases, Maas hospital Pantein, Boxmeer)
patients and their partners will be sent a letter with the
invitation to participate in the study. One week later the
researcher calls the patients to answer possible questions
and asks whether the patient and partner are interested
in participation. If so, they are invited for a research
interview at the RUNMC.
Eligibility
We include patients and/or partners of patients, who are
(a) diagnosed with cytologically or histologically proven
non-small cell lung cancer or small cell lung cancer and
(b) have received or are still under treatment. Exclusion
criteria for both patient and partner include: (a) being
under 18 years of age, (b) not being able to understand
or use the Dutch language, (c) former participation in
MBSR or Mindfulness-Based Cognitive Therapy (MBCT),
(d) current and regular treatment by psychologist or
psychiatrist, (e) current participation in other psychosocial
programme and (f ) physical or cognitive (<26 on the
Mini-Mental State Examination (MMSE)) impairments
hampering participation in MBSR training or completion
of questionnaires.
Baseline
Patients and partners are interviewed to obtain demo-
graphics and clinical characteristics, after which they are
screened for cognitive impairments with the MMSE
[33]. After that, baseline questionnaires, including the
Distress Thermometer (DT) [34,35], are administered,
followed by randomization. Table 1 shows the assessment
instruments and time points at which the questionnaires
are administered to patients and partners.
Randomization
Randomization is stratified according to setting and
minimized for (a) stage of disease (curative versus pallia-
tive), (b) baseline level of anxiety and depressive symp-
toms (anxiety or depression subscale score of Hospital
Anxiety and Depression Scale (HADS) <8 versus ≥8),
(c) treatment during MBSR (no treatment versus chemo-
and/or radiotherapy) and (d) participation (patient alone
versus partner alone versus patient and partner together).
Randomization is computerized, using a randomization
website, specifically designed for this study, on which the
researcher can fill out the required data. The researcher
communicates treatment allocation to the nurse practi-
tioner, who informs the patient and/or partner.
Follow-up assessments
Follow-up assessments take place post intervention and
at three-month follow-up. Participants who have access
to the internet and have an email address receive the
questionnaires online. If not, they receive the question-
naires on paper along with a reply envelope. In case of
drop-out, the researcher tries to contact the participant
by phone to complete a minimum set of outcome mea-
sures and to identify the main reason for drop-out.
Intervention
The MBSR curriculum used is primarily based on the
Mindfulness-Based Stress Reduction programme as de-
veloped by Kabat-Zinn [28] but contains some elements
of the MBCT programme by Segal, Williams and
Teasdale [29], like psycho-education on the interrelated-
ness of feelings and thoughts. Moreover, some modifica-
tions have been made to make the intervention more
suitable for patients with lung cancer and their partners,
such as psycho-education about grief [36]. In addition, a
mindful communication exercise in which partners talk
with each other about the cancer was added. The
programme consists of 8 weekly 2.5-hour sessions, a silent
day between session six and seven and home practice as-
signments of about 45 minutes, 6 days per week. Partici-
pants receive a set of CDs with guided mindfulness
meditation exercises for home practice and a folder with
information and home practice instructions for the forth-
coming week. Table 2 shows the content of the MBSR
programme per session. The MBSR courses are taught by
mindfulness teachers with extensive training in MBSR.
They all fulfil the advanced criteria of the Center for
Mindfulness of the University of Massachusetts Medical
School [37] and maintain a regular personal meditation
practice. Teachers were trained, supervised and assessed
to ensure their competency levels met the qualification
criteria to instruct the MBSR classes. During the trial,
teachers will receive weekly supervision and a number
of sessions will be videotaped to evaluate competence and
adherence with the Mindfulness-Based Interventions –
Teaching Assessment Criteria [38].
Outcome measures
Primary outcome measure
Psychological distress The primary outcome measure is
the total score on the HADS [39-41], which is developed
to measure psychological distress in somatic patient
populations. It consists of a 7-item anxiety (HADS-A)
and 7-item depression (HADS-D) subscale. The HADS
shows good psychometric properties in the general med-
ical population, including oncology patients [42]. In-
ternal consistency as measured with Cronbach’s α varied
from .84 to .90 [40,42].Test-retest reliability was good as
Pearson’s r > .80 were obtained [40,43]. Though the cut-
off scores of the HADS vary among populations [44], in
lung cancer patients they have found to be <8 versus ≥8
on the HADS-A or HADS-D [45]. The HADS has been
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shown to be highly correlated with the Beck Depression
Inventory [42]. It has previously been used in interven-
tion studies of mindfulness and shown to be sensitive to
change (e.g. [46]).
Secondary outcome measures
Quality of life (only for patients) The European Organ-
isation for Research and Treatment of Cancer (EORTC)
Core Quality of Life Questionnaire (QLQ-C30) [47] is
included, along with the supplemental Lung Cancer ques-
tionnaire module (QLQ-LC13) [48]. The QLQ-C30 is
designed to use in clinical trials on physical treatments
for cancer patients. It incorporates five functional scales
(physical, role, cognitive, emotional, social), three symp-
tom scales (fatigue, pain, nausea and vomiting), a global
health and quality of life scale and an array of single-item
symptom measures. After revisions in the role function-
ing, global health and physical functioning scale, internal
consistency of the subscales varied between .65 and .94,
except for the cognitive functioning scale with α varying
from .56 to .63 [47,49,50]. Test-retest reliability varied
from .63 to .86 [51]. The lung cancer questionnaire mod-
ule is designed to supplement the core questionnaire and
comprises specific symptoms associated with lung cancer
(coughing, haemoptysis, dyspnoea, pain) and side-effects
from conventional chemo- and radiotherapy (hair loss,
neuropathy, sore mouth, dysphagia). While the multi-item
dyspnoea scale showed high internal consistency, the pain
subscale did not. When combined with the dyspnoea and
pain items of the core questionnaire, both the dyspnoea
(α = .86) and pain (α = .71) subscale showed high internal
consistency. Since the QLQ-C30 and QLQ-LC13 are
mainly focused on physical symptoms, we added the items
Social Interaction and Alertness Behavior of the Sickness
Impact Profile (SIP) [52]. Internal consistency was .94 and
test-retest reliability was .92. The SIP correlated with self-
assessed sickness and dysfunction [52].
Caregiver appraisal (only for partners) We use the 9-
item Self-Perceived Pressure from Informal Care (SPPIC)
[53] to assess the extent to which caregiving is experienced
as burdensome. To also measure positive aspects of care-
giving, the 9-item subscale Care-Derived Self-Esteem of
the Caregiver Reaction Assessment (CRA-SE) [54] is in-
cluded. Internal consistency of the SPPIC was .79 and of
the CRA-SE was .73. The SPPIC and CRA-SE were unre-
lated to each other [55].
Relationship quality To measure relationship satisfaction
we included the 10-item Satisfaction subscale of the Invest-
ment Model Scale (IMS-S) [56]. The IMS-S starts with 5
items that measure concrete examplars of satisfaction, to
Table 1 Measurements and corresponding time points for patient and partner
Measure Target T0 T1 T2
pt pr pt pr pt pr
MMSE Cognitive impairments x x
DT General distress x x
HADS Psychological distress x x x x x x
QLQ-C30 Quality of life x x x
QLQ-LC13 Quality of life x x x
SIP Impact of sickness x x x
SPPIC Caregiver burden x x x
CRA-SE Caregiver self-esteem x x x
IMS-S Relationship satisfaction x x x x x x
MIS Communication about cancer x x x x x x
SAIL Spirituality x x x x x x
FFMQ Mindfulness skills x x x x x x
SCS Self-compassion x x x x x x
RRS-EXT Rumination x x x x x x
IES Psychological stress reaction x x x x x x
Diary Health care use, work absence Monthly during study period for pt
Calendar Mindfulness adherence Monthly during study period for pt and pr
Note. T0 = Baseline measurement; T1 = Post-intervention measurement; T2= 3-month follow-up measurement; pt = Patient; pr = Partner; MMSE = Mini Mental State
Examination; DT = Distress Thermometer; HADS = Hospital Anxiety and Depression Scale; QLQ-C30 = Quality of Life – Cancer; QLQ-LC13 = Quality of Life – Lung Cancer;
SIP = Sickness Impact Profile; SPPIC = Self-Perceived Pressure from Informal Care; CRA-SE = Caregiver Reaction Assessment – Care-Derived Self-Esteem; IMS-S = Investment
Model Scale-Satisfaction; MIS = Mutuality and Interpersonal Sensitivity; SAIL = Spiritual Attitude and Involvement List; FFMQ = Five Facet Mindfulness Questionnaire;
SCS = Self-Compassion Scale; RRS-EXT = Rumination Response Scale – Extended Version; IES = Impact of Event Scale.
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enhance the comprehensibility of the global items, which
are utilized to form the construct. Internal consistency
varied from .79 to .95 and the IMS-S was related to the
Dyadic Adjustment Scale. Also, the Mutual Interpersonal
Sensitivity scale (MIS) [57] is included to measure commu-
nication between partners about the cancer. It contains 18
items and is divided into two scales: open communication
and avoiding negative thoughts about the cancer.
Spirituality is measured with the Spiritual Attitude and
Involvement List (SAIL) [58] and consists of 26 items,
divided into the subscales meaningfulness, trust, accept-
ance, caring for others, connectedness with nature,
transcendent experiences, and spiritual activities. The in-
ternal consistency varied from .74 to .88 and test-retest
reliability varied from .77 to .92. All subscales, except for
connectedness with nature, were related with the
Functional Assessment of Chronic Illness Therapy –
Spiritual Well-Being Scale.
Costs (only for patients)
The cost-effectiveness evaluation is carried out from a
societal perspective, considering direct as well as indirect
health costs. Data on costs are collected prospectively
using a diary in which participants register a) health
care utilization: the type of care and its duration, and
b) cancer-related absence from work. Unit cost estimates
are derived from the national manual for cost prices in the
health care sector [59]. Costs of reduced ability to work
are estimated using the friction costs method, which re-
sults in a more realistic estimate than the human capital
approach [60]. Treatment costs of MBSR are calculated
Table 2 Content of MBSR programme per session
Theme of session Meditation exercise Didactic teaching Homework
1. Automatic pilot - Bodyscan - Intention of participating - Bodyscan
- Raisin exercise - Eating one meal mindfully
- Attention for routine activity




- Sitting mediation with focus
on breath
- Attention for breath
- Awareness of pleasant events
- Attention for routine activity
3. Observing limits - Yoga while lying down - Seeing exercise to demonstrate
difference between observation
and interpretation
- Bodyscan or yoga
- 3-min breathing space - Sitting meditation
- Awareness of unpleasant events
- 3-min breathing space
4. Opening up to distress - Sitting mediation with focus
on breath, body and sound
- Interrelatedness of feelings,
thoughts and bodily sensations
- Bodyscan or yoga
- Sitting meditation
- 3-min breathing space - Psychoeducation about grief
- Awareness of stress reactions
- 3-min breathing space
5. Responding to distress - Sitting mediation with focus
on breath, body, sound,
thoughts, difficulty
- Reacting versus responding - Meditation by choice
- Coping with grief - Awareness of reaction in difficult situation
- Walking meditation - Awareness of communication difficulties
- 3-min breathing space - 3-min breathing space
6. Mindful communication - Yoga in standing position - Mindful communication exercise
about effect of lung cancer with
their own partner
- Sitting meditation or yoga
- 3-min breathing space - Awareness of communication
- 3-min breathing space during stress
Silent day - Varying meditation exercises
- Silent lunch and tea break
7. Taking care of yourself - Sitting meditation ending in
choiceless awareness
- Exercise on taking care of yourself by
examining how to improve balance in life
- Meditation without CD
- Yoga or walking meditation
- Reflect on training
- 3-min breathing space
8. The rest of your life - Bodyscan - Reflection on training - Further sources of information
- Short sitting meditation - Maintaining practice
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using activity-based-costing methods, thus measuring ac-
tual resources (time of therapist, time of patients, facilities)
used. All unit cost prices are adjusted to 2013 prices. Unit
cost estimates are combined with resource utilization data
to obtain a net cost per patient over the entire follow-up
period.
Process measures
Mindfulness skills are examined with the 39-item Five
Facet Mindfulness Questionnaire (FFMQ) [61,62]. The
FFMQ is based on an exploratory factor analysis of five
mindfulness measures, which allowed items from differ-
ent instruments to form factors, providing an empirical
integration of these independent attempts to operationalize
mindfulness. This led to the following five subscales: ob-
serving, describing, acting with awareness, non-judging of
inner experience and non-reactivity to inner experience.
Internal consistency varied from .72 to .93 among the dif-
ferent subscales. Most subscales were related to meditation
experience, Psychological Well-Being scales and psycho-
logical symptoms, including the Brief Symptom Inventory
[61]. FFMQ is sensitive to change in mindfulness-based
interventions and is found to mediate the relationship be-
tween mindfulness practice and improvements in psycho-
logical symptoms (e.g. [63]).
Self-compassion is assessed with the Self Compassion
Scale (SCS) [64,65], which has 26 items and is divided into
six subscales: self-kindness versus self-judgment, common
humanity versus isolation, and mindfulness versus over-
identification. Internal consistency of the different subscales
varied from .75 to .81 and test-retest reliability varied from
.80 to .93. SCS correlated moderately with self-esteem mea-
sures, including the Rosenberg Self-Esteem Scale. Further-
more, whereas the self-esteem measures correlated
significantly with the Narcissistic Personality Inventory, the
SCS was unrelated to narcissism [64]. SCS is sensitive to
change through mindfulness-based interventions and is
found to mediate MBCT’s treatment effects [66].
To measure rumination we administered the ex-
tended version of the Ruminative Response Scale (RRS-
EXT) [67, Raes and Hermans: The revised version of the
Dutch Ruminative Response Scale, unpublished instru-
ment]. The RRS-EXT contains 26 items in which a more
adaptive thinking style (i.e. reflection) is distinguished
from a more maladaptive one (i.e. brooding). Internal
consistency varied from .72 to .77 and test-retest reliabil-
ity varied from .60 to .62 for the brooding and reflection
subscales. The concept of rumination seems to be sensi-
tive to change through mindfulness-based interventions
and has been shown to mediate the effect of MBSR on
depressive symptoms in oncology patients [68].
The psychological stress reaction is measured with
the 15-item Impact of Event Scale (IES) [69,70], which
assesses two categories of responses: intrusive experi-
ences and avoidance of thoughts and images associated
with the event. Internal consistency varied from .65 to .92
[71] and test-retest reliability varied from .79 to .87 among
the subscales [69]. IES correlated with anxiety and depres-
sion subscales of the General Health Questionaire.
Adherence to MBSR is assessed during the entire study
period with a calendar on which participants in the
MBSR condition fill out on a daily basis whether they
adhere to the mindfulness exercises: either formal prac-
tice (e.g. meditation exercise like the bodyscan), informal
practice (e.g. activity with awareness) or no exercise. Ad-
herence to MBSR has been shown to mediate the effects
of MBCT on depressive symptoms [72].
Statistical analysis plan
Sample size
To determine the required sample size, first the sample size
was calculated that would be needed for a simple t-test and
subsequently it was corrected for clustering, repeated mea-
surements and baseline. A two-sided t-test on the total
HADS score [39,40] (i.e. our primary outcome measure,
examining psychological distress (HADS-total), anxiety
symptoms (HADS-A) and depressive symptoms (HADS-
D)) would require 64 participants in each group to have
80% power to detect a medium-sized difference (effect
size = 0.5) with alpha = 0.05. To correct for clustering, we
multiplied this sample size of 64 with the design factor (1 +
(n − 1) * ICC), where n denotes the cluster size and where
ICC denotes the intra-cluster correlation. In our study, the
treatment groups will consist of 14 people, of whom about
7 will be patients. With n = 7 and an estimated ICC = 0.01.
[72], the correction factor equals 1.06. To correct for
repeated measurements and the use of the baseline meas-
urement as a covariate, we multiplied the required sample
size by the design factor 1þ ρð Þ=2−ρ20
 
; where ρ de-
notes the correlation between the post-treatment
HADS measurements, and ρ0 denotes the correlation
between the baseline HADS with the post-treatment
HADS measurements. With ρ = 0.8 and ρ = 0.5 as conser-
vative estimates, the second design factor equals 0.65. Con-
sequently, after correction for clustering and covariates, we
arrived at a required sample size of 0.65 * 1.06 * 64 = 44
patients per arm. So 88 patients with lung cancer would be
required for the study. Based on our pilot study [van den
Hurk, Schellekens, Molema, Speckens and van der Drift, in
preparation], we expect a 20% drop-out rate. Therefore,
we intend to include 110 patients and 110 partners.
Primary analyses
The samples of lung cancer patients and partners will be
analyzed separately. Baseline characteristics of the
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population will be compared between MBSR and control
group to ensure that key variables were evenly distrib-
uted by randomization. First, analyses will be based on
the intention-to-treat approach. Next, we will perform
per-protocol analyses with the treatment-adherent sample
(i.e. in the MBSR condition participants have to attend at
least four of the eight MBSR sessions [73] and in the TAU
condition participants do not attend a mindfulness-based
programme).
We will use linear mixed models to analyze all out-
come variables (i.e. psychological distress, quality of life
(only for patient), caregiver appraisal (only for partner),
relationship quality and spirituality), with treatment as
fixed factor, baseline measurement as covariate and a
random intercept based on MBSR group. This procedure
will use all observed data in our analyses. In addition,
Cohen’s d effect size [74] will be reported based on the
difference between the group means on baseline and
follow-up scores, divided by the pooled standard devi-
ation at baseline and follow-up.
Secondary analyses
Cost effectiveness The quality of life measures (i.e.
QLQ-C30; QLQ-LC13) will be used to calculate Quality
of Adjusted Life Years (QALYs) for each individual.
Costs and effects (in terms of QALYs) will be combined
in the incremental cost-effectiveness ratio (ICER). The
ICER expresses cost-effectiveness in terms of incremental
costs per QALY gained. To estimate confidence intervals
for the mean of the ICER a non-parametric bootstrapping
method will be used, performing 1000 replications of the
original data. In order to express the implications of the
cost-effectiveness results more clearly, a cost-acceptability
curve will be constructed. In case of dominance, a full cost
analysis will be conducted to estimate the mean savings
per patient per year.
Mediation analyses To examine the possible underlying
mechanisms of change in MBSR, mediation analyses will
be conducted. Only the data of the treatment-adherent
sample will be included in these analyses. By means of a
multiple mediation model suggested by Preacher and
Hayes [75], we will test the mediating effect of mindful-
ness skills, self-compassion, rumination and adherence
to MBSR on psychological distress, quality of life (only in
patients), caregiver appraisal (only in partners), relationship
quality and spirituality.
Discussion
In the last ten years MBSR has not only proven to be a
feasible and acceptable intervention in cancer patients
[76], but it also seems to be effective in reducing psycho-
logical distress [30]. However, the generalization of these
results is limited because most participants were female
patients with breast cancer. A large part of lung cancer
patients already have advanced cancer at time of diagno-
sis and are confronted with a poor prognosis and low
health status. Consequently, they more often report psy-
chological distress than patients with other diagnoses of
cancer [8,9]. Hence, it is not yet clear whether MBSR is
a feasible, acceptable and effective intervention in patients
with lung cancer. Moreover, little is known about the ef-
fectiveness of MBSR in partners of cancer patients [30],
though they also often report psychological distress.
Our pilot study of 19 lung cancer patients and 16 part-
ners participating in an MBSR course, provides prelimin-
ary evidence that MBSR is feasible and acceptable in this
population (van den Hurk, Schellekens, Molema, Speck-
ens and van der Drift, in preparation). The current trial
will answer the question whether MBSR is effective in
patients with lung cancer and their partners.
We started enrolment of participants in February 2012.
At the moment, we think recruiting a sufficient number of
patients and partners will be a challenge due to rapidly
fluctuating health status and sudden changes in cancer
treatment [77]. The main reasons for declining participa-
tion in patients is ‘being too ill’ or that it is ‘too much of a
burden during chemo and/or radiotherapy’. Furthermore,
no perceived need or motivation for the training is com-
monly mentioned. Among partners, participation is highly
depending on whether the patient is willing to participate.
Although partners can take part separately, partners who
are interested do often not participate when the patients
decline participation.
Considering the difficulty of studying lung cancer pa-
tients and their partners [77], our trial will offer valuable
information on whether MBSR, as one of the few avail-
able psychosocial care programmes, contributes to the
alleviation of their psychological distress.
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